OSLO, 3 January 2023: 
EXACT Therapeutics AS ("EXACT-Tx" or the "Company") has today granted a total of 162,000 share options to employees of the Company, of which a total of 90,000 share options have been granted to primary insiders of the Company. Each option, when exercised, gives the right to acquire one share in the Company. The shares will be subject to a 12-month lock-up, subject to certain exemptions.
 
The share options expires one week after the date of the release of the Company's half year results in 2027  and vest over a period of three years on the date of the release of the half year results, whereby 25% vest in 2023, 25% vest in 2024 and 50% vest in 2025. All options have an exercise price of NOK 12,69, which is subject to adjustment in the event of i) a change in the share capital, ii)  a rights issue or repair issue, or iii) dividends or other distributions in cash or in kind. The following primary insiders have been granted share options:

-	Amir Snapir (Chief Medical Officer) has been granted 60,000 share options. Following the grant, Snapir holds 60,000 share options in EXACT-Tx. 

-	John M. Edminson (Chief Financial Officer) has been granted 30,000 share options. Following the grant, Edminson holds 30,000 share options in EXACT-Tx.

This information is subject to the disclosure requirements in Regulation EU 596/2014 (MAR) article 19 number 3 and section 5-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Per Walday, CEO, per.walday@exact-tx.com

About EXACT-Tx:
EXACT-Tx is a Norwegian clinical-stage precision health company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101) activated by ultrasound for enhanced drugtargeting deployed in multiple indications to enhance the therapeutic efficacy of medicines through the use of ultrasound-mediated drug delivery, for patients across multiple diseases. www.exact-tx.com